Active	Status	Sponsor type	Region	Phase	Filter
15 Active 11 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mohty, Mohamad
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Recruiting	2b	102	Europe, Canada, US, RoW	DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan	ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC	Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma	10/24	04/25
IFM 2021-01, NCT05572229: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma	Recruiting	2	74	Europe	Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide	University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium	Multiple Myeloma	05/25	09/30
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma	Completed	1/2	272	Europe, Canada, Japan, US, RoW	Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	07/24	11/24
NCT03309111: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma	Completed	1	81	Europe, US	ISB 1342	Ichnos Sciences SA, Glenmark Pharmaceuticals S.A.	Relapsed/Refractory Multiple Myeloma	12/23	12/23
DESCAR-T, NCT04328298: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment	Recruiting	N/A	5000	Europe		The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb	Hematopathology Eligible or CAR-t Cell Treatment	12/38	12/38